SCHEMBL4812263

SCHEMBL4812263

O=C(CO)N[C@H](CO)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 3/20 0.56
MME P08473 6/20 0.53
CA2 P00918 5/20 0.41
CA1 P00915 3/20 0.41
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
CA4 P22748 1/20 0.39
FOLH1 Q04609 1/20 0.37
RIMKLA Q8IXN7 1/20 0.37
NAALAD2 Q9Y3Q0 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
ALOX15 P16050 1/20 0.37
NFKB1 P19838 1/20 0.37
PTGS2 P35354 1/20 0.37
THPO P40225 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1995531 1.00 TGFBR1 (0.56) TGFBR1MMECA2CA1FNTA
SCHEMBL1995530 1.00 TGFBR1 (0.56) TGFBR1MMECA2CA1FNTA
SCHEMBL4812250 0.83 TGFBR1 (0.54) TGFBR1MMECA2CA1FNTA
SCHEMBL6315187 0.83 TGFBR1 (0.54) TGFBR1MMECA2CA1FNTA
SCHEMBL16314008 0.81 TGFBR1 (0.52) TGFBR1MMECA2CA1FNTA
SCHEMBL7753529 0.81 MME (0.42) TGFBR1MMECA2CA4FOLH1
SCHEMBL11303240 0.81 TGFBR1 (0.52) TGFBR1MMECA2CA1FNTA
SCHEMBL4193694 0.81 MME (0.55) TGFBR1MMECA2CA1FNTA
SCHEMBL783083 0.81 TGFBR1 (0.57) TGFBR1MMECA2CA1FNTA
SCHEMBL783082 0.81 TGFBR1 (0.57) TGFBR1MMECA2CA1FNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470678-B2 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism ASTRAZENECA AB (SE) 2008-12-30 US disclosed
US-20050239766-A1 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism ASTRAZENECA AB (SE) 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239766-A1 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism CYP46A1, CYP27A1, CYP7A1 TGFBR1 4635/4885MME 637/4885CA2 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.